Acta Haematologica This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Non-immunotherapy approaches for Relapsed or Refractory AML: an update for 2024
Acta Haematol. 2023 Oct 31. doi: 10.1159/000534897. Online ahead of print.ABSTRACTBACKGROUND: Relapsed or refractory (R/R) acute myeloid leukemia (AML) is a challenging, high-risk, clinical scenario with a dismal outcome. Recent insights on the genetic, epigenetic, and metabolic events that drive clonal progression and the advent of novel therapies resulted in the incorporation of several new targeted therapies, alone or in combination, in the R/R setting with the aim of improving response rates and survival. Herein we review current challenges and future opportunities with non-immunotherapeutic approaches to treat R/R AML...
Source: Acta Haematologica - October 31, 2023 Category: Hematology Authors: Shira Buchrits Ofir Wolach Source Type: research

Importance of MRD in the era of targeted therapies in CLL
Acta Haematol. 2023 Oct 30. doi: 10.1159/000534846. Online ahead of print.ABSTRACTThe level of Minimal residual disease (MRD), often binarized into detectable or undetectable MRD according to certain thresholds, is strongly associated with long-term outcomes after chemo- and chemoimmunotherapy. Driven by our improved understanding of the biology of CLL, the recent decade has shown a shift from chemotherapy-based regimens to regimens based on targeted agents that exploit distinct biological vulnerabilities of CLL. These targeted agents can be broadly classified into inhibitors of Bruton Tyrosine Kinase (BTK) and BCL2 as wel...
Source: Acta Haematologica - October 30, 2023 Category: Hematology Authors: Othman Al Sawaf Source Type: research

Frontline therapy in Chronic Lymphocytic Leukemia
Acta Haematol. 2023 Oct 27. doi: 10.1159/000534730. Online ahead of print.ABSTRACTThe treatment landscape of chronic lymphocytic leukemia (CLL) has tremendously evolved in the last decades thanks to the introduction of more effective therapies. Front-line therapy for patients with CLL includes chemoimmunotherapy (CIT) and pathway inhibitors (PI) (i.e., Bruton tyrosine kinase inhibitors and BCL2 inhibitors); the latter have proved to be more effective than CIT mainly in patients with high-risk features (eg, TP53 aberrations, unmutated IGHV) with acceptable toxicity. Combinations of PIs are playing a protagonist role as fron...
Source: Acta Haematologica - October 29, 2023 Category: Hematology Authors: Miguel Arguello-Tomas Nil Albiol Carol Moreno Source Type: research

Addendum to the German Consensus Recommendations on Ponatinib in the Treatment of Chronic Myeloid Leukemia
Acta Haematol. 2023 Oct 17. doi: 10.1159/000533666. Online ahead of print.ABSTRACTBACKGROUND: Based on the new data from the primary analysis of the OPTIC (Optimizing Ponatinib Treatment in CP-CML) trial on dose optimization of ponatinib in patients with chronic phase (CP)-CML, the German consensus paper on ponatinib published in 2020 (Saussele S et al., Acta Haematol. 2020) has been updated in this addendum.SUMMARY: Focus is on the update of efficacy and safety of ponatinib, reflecting the new data set, as well as the update of the benefit-risk assessment and recommendations for ponatinib starting dose in CP-CML - provide...
Source: Acta Haematologica - October 17, 2023 Category: Hematology Authors: Susanne Saussele Paul La Ros ée Alexander Kiani Wilhelm Haverkamp Kathleen Jentsch-Ullrich Frank Stegelmann Christina Rieger Cornelius F Waller Georg-Nikolaus Franke Christian Junghanss Rudolf Kirchmair Markus Theurl Philipp le Coutre Source Type: research